Opinion|Videos|November 17, 2026

BRAF V600E mCRC: Targeted Therapy and Rechallenge Strategies

Encorafenib and cetuximab have transformed outcomes for BRAF V600E-mutant colorectal cancer, while liquid biopsy-guided anti-EGFR rechallenge offers a promising, biomarker-selected path in later treatment lines.

In “BRAF V600E mCRC: Targeted Therapy and Rechallenge Strategies,” the panel discusses how targeted therapy and molecular reassessment are changing treatment sequencing in metastatic colorectal cancer. Dr. Fakih reviews the movement of encorafenib and cetuximab into first-line treatment for BRAF V600E-mutant disease based on the BREAKWATER trial. As patients experience longer periods of disease control, new questions are emerging about what should happen after progression on a regimen that already includes BRAF- and EGFR-directed therapy.

One area of interest is whether targeted therapy should ever be continued beyond progression or reintroduced later. Dr. Fakih notes that slower and oligoprogressive patterns are being seen more often in patients receiving targeted therapy and raises concern that withdrawing treatment against a strong oncogenic driver could lead to rapid progression in some cases. His group has reported disease stabilization with rechallenge in selected patients, but he stresses that this strategy requires prospective study and should not be generalized.

Dr. Parseghian then discusses anti-EGFR rechallenge guided by circulating tumor DNA. Resistance alterations that emerge during therapy can decline during an anti-EGFR-free interval. If ctDNA shows that the tumor remains RAS wild-type and relevant resistance mutations are no longer detected, selected patients may be candidates for anti-EGFR rechallenge. The episode highlights how repeated molecular assessment is increasingly being used to guide targeted treatment sequencing in later-line care.

Our next episode, “Individualizing Third-Line Treatment in mCRC,” examines how molecular findings, prior treatment, clinical factors, and patient preferences come together in later-line decision-making.

Related to this article